233 related articles for article (PubMed ID: 29879685)
61. Phenotype of definite familial hypercholesterolemia with negative genetic study in Argentina.
Corral P; Bañares V; Sáenz B; Zago V; Sarobe A; López G; Berg G; Schreier L
Arch Cardiol Mex; 2020; 90(2):130-136. PubMed ID: 32897268
[TBL] [Abstract][Full Text] [Related]
62. Spectrum of mutations of familial hypercholesterolemia in the 22 Arab countries.
Alhababi D; Zayed H
Atherosclerosis; 2018 Dec; 279():62-72. PubMed ID: 30415195
[TBL] [Abstract][Full Text] [Related]
63. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
[TBL] [Abstract][Full Text] [Related]
64. Electronic health records to facilitate continuous detection of familial hypercholesterolemia.
Pepplinkhuizen S; Ibrahim S; Vink R; Groot B; Stroes ESG; Bax WA; Cornel JH
Atherosclerosis; 2020 Oct; 310():83-87. PubMed ID: 32927124
[TBL] [Abstract][Full Text] [Related]
65. A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia.
Ademi Z; Watts GF; Juniper A; Liew D
Int J Cardiol; 2013 Sep; 167(6):2391-6. PubMed ID: 23490080
[TBL] [Abstract][Full Text] [Related]
66. Improving the identification of patients with a genetic diagnosis of familial hypercholesterolaemia in primary care: A strategy to achieve the NHS long term plan.
Ingoe L; Potter A; Musson S; Neely D; Pilkington G; Allen AJ; Reay D; Luvai A; McAnulty C; Camm N; Berry I; Nichols J; Forbes G; Newton J; Carey PE
Atherosclerosis; 2021 May; 325():38-45. PubMed ID: 33892327
[TBL] [Abstract][Full Text] [Related]
67. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
68. Genetic Architecture of Familial Hypercholesterolaemia.
Sharifi M; Futema M; Nair D; Humphries SE
Curr Cardiol Rep; 2017 May; 19(5):44. PubMed ID: 28405938
[TBL] [Abstract][Full Text] [Related]
69. Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
Pek SLT; Dissanayake S; Fong JCW; Lin MX; Chan EZL; Tang JI; Lee CW; Ong HY; Sum CF; Lim SC; Tavintharan S
Atherosclerosis; 2018 Feb; 269():106-116. PubMed ID: 29353225
[TBL] [Abstract][Full Text] [Related]
70. Improving identification of familial hypercholesterolaemia in primary care: derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT).
Weng SF; Kai J; Andrew Neil H; Humphries SE; Qureshi N
Atherosclerosis; 2015 Feb; 238(2):336-43. PubMed ID: 25555265
[TBL] [Abstract][Full Text] [Related]
71. Incorporation of genetic testing significantly increases the number of individuals diagnosed with familial hypercholesterolemia.
Brown EE; Byrne KH; Davis DM; McClellan R; Leucker T; Jones SR; Martin SS
J Clin Lipidol; 2020; 14(3):331-338. PubMed ID: 32220565
[TBL] [Abstract][Full Text] [Related]
72. Diagnosis and treatment of familial hypercholesterolaemia.
Hovingh GK; Davidson MH; Kastelein JJ; O'Connor AM
Eur Heart J; 2013 Apr; 34(13):962-71. PubMed ID: 23416791
[TBL] [Abstract][Full Text] [Related]
73. Genomics of familial hypercholesterolaemia.
Alves AC; Chora JR; Bourbon M
Curr Opin Lipidol; 2019 Apr; 30(2):148-150. PubMed ID: 30844855
[No Abstract] [Full Text] [Related]
74. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.
Sturm AC; Knowles JW; Gidding SS; Ahmad ZS; Ahmed CD; Ballantyne CM; Baum SJ; Bourbon M; Carrié A; Cuchel M; de Ferranti SD; Defesche JC; Freiberger T; Hershberger RE; Hovingh GK; Karayan L; Kastelein JJP; Kindt I; Lane SR; Leigh SE; Linton MF; Mata P; Neal WA; Nordestgaard BG; Santos RD; Harada-Shiba M; Sijbrands EJ; Stitziel NO; Yamashita S; Wilemon KA; Ledbetter DH; Rader DJ;
J Am Coll Cardiol; 2018 Aug; 72(6):662-680. PubMed ID: 30071997
[TBL] [Abstract][Full Text] [Related]
75. Cascade screening for familial hypercholesterolemia: Practical consequences.
Louter L; Defesche J; Roeters van Lennep J
Atheroscler Suppl; 2017 Nov; 30():77-85. PubMed ID: 29096865
[TBL] [Abstract][Full Text] [Related]
76. Case-finding and genetic testing for familial hypercholesterolaemia in primary care.
Qureshi N; Akyea RK; Dutton B; Humphries SE; Abdul Hamid H; Condon L; Weng SF; Kai J;
Heart; 2021 Dec; 107(24):1956-1961. PubMed ID: 34521694
[TBL] [Abstract][Full Text] [Related]
77. Clinical Diagnostic Criteria of Familial Hypercholesterolemia - A Comparison of the Japan Atherosclerosis Society and Dutch Lipid Clinic Network Criteria.
Tada H; Okada H; Nomura A; Usui S; Sakata K; Nohara A; Yamagishi M; Takamura M; Kawashiri MA
Circ J; 2021 May; 85(6):891-897. PubMed ID: 33268660
[TBL] [Abstract][Full Text] [Related]
78. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.
Spencer SJ; Jones LK; Guzauskas GF; Hao J; Williams MS; Peterson JF; Veenstra DL
J Clin Lipidol; 2022; 16(5):667-675. PubMed ID: 35961838
[TBL] [Abstract][Full Text] [Related]
79. Feasibility of improving identification of familial hypercholesterolaemia in general practice: intervention development study.
Qureshi N; Weng S; Tranter J; El-Kadiki A; Kai J
BMJ Open; 2016 May; 6(5):e011734. PubMed ID: 27231005
[TBL] [Abstract][Full Text] [Related]
80. Prevalence of clinical familial hypercholesterolaemia among patients with high cholesterol levels.
Martinsen MH; Hedegaard BS; Klausen IC; Mortensen MB
Dan Med J; 2019 Nov; 66(11):. PubMed ID: 31686647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
